ILLUMINA, INC. (ILMN)
About ILLUMINA, INC.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $4.3B
- Net income
- $850.0M
- Total assets
- $6.6B
- Market cap
- $24.6B
- Gross margin
- 66.1%
- Operating margin
- 18.6%
- Net margin
- 19.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.3B
- Cost of revenue
- $1.5B
- Gross profit
- $2.9B
- Operating expenses
- $2.1B
- Operating income
- $807.0M
- Income tax
- $236.0M
- Net income
- $850.0M
- EPS (basic)
- $5.47
- EPS (diluted)
- $5.45
Balance sheet
- Total assets
- $6.6B
- Current assets
- $3.3B
- Total liabilities
- $3.9B
- Current liabilities
- $1.6B
- Shareholders’ equity
- $2.7B
Cash flow
- Operating cash flow
- $1.1B
- Investing cash flow
- -$55.0M
- Financing cash flow
- -$744.0M
- Net cash flow
- $291.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $24.6B
- P/E ratio
- 35.6
- EPS (diluted)
- $5.45
- Shares outstanding
- 126.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 28, 2000
Illumina, Inc. (ILMN) Stock Price
- Profitable — net income of $850.0M in FY2025.
- Revenue grew 34% from FY2020 to FY2025.
- Gross margin of 66.1%, net margin 19.6%.
- Trading near its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 35.6.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review ILLUMINA, INC..
Write a review
News about ILLUMINA, INC.
News & sentiment via Polygon.io
Illumina, Inc.: frequently asked questions
Is Illumina, Inc. an American company?
Yes — Illumina, Inc. is an American company headquartered in San Diego, California. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.
Where is Illumina, Inc. headquartered?
Illumina, Inc. is headquartered in San Diego, California, United States.
Is Illumina, Inc. publicly traded?
Yes — Illumina, Inc. is a publicly traded company. Its stock trades under the ticker symbol ILMN on the NASDAQ.
What does Illumina, Inc. do?
Illumina, Inc. is an American Medical Devices company in the Health & Beauty sector.
When was Illumina, Inc. founded?
Illumina, Inc. was founded in 1998.
